Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly

[1] Katznelson L(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951

[2] Laws ER(2018)Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis Eur J Endocrinol 179 59-71

[3] Melmed S(2018)A Consensus statement on acromegaly therapeutic outcomes Nat Rev Endocrinol 14 552-561

[4] Molitch ME(2019)Acromegaly Nat Rev Dis Primers 5 20-131

[5] Murad MH(2015)A structural and functional acromegaly classification J Clin Endocrinol Metab 100 122-115

[6] Utz A(2017)Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance Pituitary 20 109-S158

[7] Wass JA(2019)Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas Gland Surg 8 S150-120

[8] Bolfi F(2017)T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective Pituitary 20 116-498

[9] Neves AF(2016)T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly Endocr Relat Cancer 23 871881-714

[10] Boguszewski CL(2013)Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience Pituitary 16 490-2455

[1] Katznelson L(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951

[2] Laws ER(2018)Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis Eur J Endocrinol 179 59-71

[3] Melmed S(2018)A Consensus statement on acromegaly therapeutic outcomes Nat Rev Endocrinol 14 552-561

[4] Molitch ME(2019)Acromegaly Nat Rev Dis Primers 5 20-131

[5] Murad MH(2015)A structural and functional acromegaly classification J Clin Endocrinol Metab 100 122-115

[6] Utz A(2017)Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance Pituitary 20 109-S158

[7] Wass JA(2019)Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas Gland Surg 8 S150-120

[8] Bolfi F(2017)T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective Pituitary 20 116-498

[9] Neves AF(2016)T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly Endocr Relat Cancer 23 871881-714

[10] Boguszewski CL(2013)Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience Pituitary 16 490-2455